Evaluation of cytochrome P450 inhibition and induction by psoralen and isopsoralen in vitro

Chinese Journal of Pharmacology and Toxicology

Volumn 26, Issue 4, 2012, Pages 522-528

  Zhong, Yu Huan ^a,b   Shen, Guo Lin ^b   Yuan, Mei ^b   Liu, Wan Hui ^a   Li, Hua ^b  

^a YANTAI UNIVERSITY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Cytochromes; Drug interactions; Isopsoralen; Liver; Microsomes; Psoralens

Indexed keywords

ANGELICIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; PSORALEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ANIMAL CELL; ARTICLE; CELL CULTURE; DEMETHYLATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYDROXYLATION; IC 50; IN VITRO STUDY; LIVER CELL; LIVER MICROSOME; NONHUMAN; PROTEIN INDUCTION; RAT;

RATTUS;

EID: 84866788971     PISSN: 10003002     EISSN: None     Source Type: Journal    
DOI: 10.3867/j.issn.1000-3002.2012.04.010     Document Type: Article

References (16)

1. Zhang HL, Wang YN, Wang JH. Advance on the chemistry and bioactivity of Psoralea sorylifolia L. [J]. Nat Prod Res Dev, 2010, 22(5):909-913, 918.
2. Zhao PW, Niu JZ, Wang JF, Wang DW, Chen JX, Wang LQ. Phytoestrogenic effects of six active components in Chinese medicine[J]. Chin Pharm J 2007, 42(24):1852-1855.
3. Li Z, Song BA. Antitumor mechanism and application prospect of psoralen[J]. J Mountain Agric Biol 2007, 26(3):255-260.
4. Song DR, Song HY, Wang YF, Guo J, Xu YY, Pan GX. Study on serum active constituents of rats intragastrically given decoction of Fructus Psoraleae[J]. China J Tradit Chin Med Pharm, 2010, 25(11):1863-1865.
5. Yang SL, Xiong YJ, Fang PF, Zhao XY. Study progression of coumarins on CYP450s[J]. Cent South Pharm, 2011,9(1):45-49.
6. Wang X, Lou YJ, Wang MX, Shi YW, Xu HX, Kong LD. Furocoumarins affect hepatic cytochrome P450 and renal organic ion transporters in mice[J]. Toxicol Lett, 2012, 209(1):67-77.
7. Fowler S, Zhang H. In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions[J]. AAPS J, 2008, 10(2):410-424.
8. Ai CH, Sun HX, Li H, Zhang XM, Dong DL. In vitro inhibition of cytochrome P450 activities by active constituents of Chinese herbal drugs[J]. Chin Pharmacol Bull, 2011, 27(4):519-523.
9. Seglen PO. Preparation of isolated rat liver cells[M] // Allen T. Introduction to Electron Microscopy for Biologists. Academic press, 1976:29-83.
10. Tchaparian EH, Houghton JS, Uyeda C, Grillo MP, Jin L. Effect of culture time on the basal expression levels of drug transporters in sandwich-cultured primary rat hepatocytes[J]. Drug Metab Dispos, 2011, 39(12):2387-2394.
11. US FDA. Guidance for industry: Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling[ EB/OL]. [2010-10-29] http://www.fda.gov/downloads/Drugs/GuidanceCompliance-RegulatoryInformation/ Guidances/ucm072101.pdf
12. Lin QH, Zhuang XM, Deng JT, Han G, Gong ZH, Li H. Metabolic interaction between rotundine and oxycodone in vitro[J]. Chin J Pharmacol Toxicol, 2009, 23(5):404-410.
13. Testa B, van de Waterbeemd H. ADME-Tox Approaches[M] // Triggle D, Taylor J. Comprehensive Medicinal Chemistry II. Beijing: Science Press, 2007:246.
14. He N, Ou-yang DS, Zhu B, Yu BN. Pharmacogenetics of drug oxidase CYP450[M] // Zhou HH. Pharmacogenetics. Beijing: People's Military Medical Press, 2003:64-68.
15. Chu V, Einolf HJ, Evers R, Kumar G, Moore D, Ripp S, et al. In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of America perspective[J]. Drug Metab Dispos, 2009, 37(7):1339-1354.
16. Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction[J]. Expert Opin Drug Metab Toxicol, 2006, 2 (6):875-894.